Overview

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Status:
Completed
Trial end date:
2016-07-27
Target enrollment:
Participant gender:
Summary
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Mirabegron